Physician profile
Robert Eden
NPI 1457307811
$24,145.67
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,216 · 2021: $1,398 · 2022: $1,747 · 2023: $2,756 · 2024: $3,874 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $7,650 · Education: $25.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,947.54 |
| Consulting Fee | $7,650.00 |
| Education | $25.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $9,126.26 | 2019-2025 | |
| Alcon Vision LLC | $2,813.37 | 2019-2025 | Clareon, Argos, Eysuvis |
| Mallinckrodt Hospital Products INC. | $1,862.69 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $1,229.79 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $1,182.13 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Sight Sciences, INC. | $903.15 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $702.87 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $669.44 | 2019-2025 | Cequa |
| Glaukos Corporation | $661.22 | 2022-2025 | Photrexa Viscous and Photrexa, Idose |
| Rxsight INC | $557.44 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $545.53 | 2020-2025 | Oxervate |
| Allergan, INC. | $502.79 | 2019-2022 | |
| Oyster Point Pharma, INC. | $498.24 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $454.15 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $346.66 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $345.24 | 2019-2023 | |
| Ocular Therapeutix, INC. | $341.33 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $278.86 | 2019-2023 | Tecnis Simplicity |
| Amgen INC. | $214.49 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $154.70 | 2025 | Izervay |
| Mallinckrodt Enterprises LLC | $152.56 | 2019 | |
| Harrow Eye, LLC | $118.69 | 2024 | Vevye, Iheezo |
| Spark Therapeutics, INC. | $91.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $85.03 | 2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $62.59 | 2022-2023 | Flarex |
| Rayner Intraocular Lenses Limited | $38.56 | 2023 | Rayone Spheric, Rayone Emv, Omidria |
| Horizon Therapeutics Plc | $38.13 | 2021-2023 | Tepezza |
| Omeros Corporation | $36.59 | 2019-2020 | |
| Genzyme Corporation | $23.85 | 2021 | |
| Thea Pharma INC. | $23.72 | 2025 | Iyuzeh |
| Shire North American Group INC | $22.09 | 2019 | |
| Leadiant Biosciences, INC. | $21.64 | 2020 | |
| Recordati_rare_diseases_inc. | $20.65 | 2024 | Cystadrops |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.